Drug patent portfolios shouldn’t just sit on the shelf—they should be engineered to win.
In pharma, the default playbook is often “file early, hope for the best, and defend later.” But the market has changed. Litigation is no longer a rare event; it’…

Hospitals are sitting on a quiet competitive advantage—and many are ignoring it.
In the pharmaceutical supply chain, “patent expiration” is often treated like a distant calendar event. But for hospital systems, it’s not a trivia question. It’s a procur…

Generic launches don’t “just happen.” They’re engineered by time, law, and leverage.
If you’re still forecasting generic drug launch dates using spreadsheets and historical averages, you’re already behind. In today’s patent landscape—where exclusivit…

The FDA Orange Book isn’t just a database—it’s a talent map.
Most people treat the Orange Book like a compliance tool: a place to confirm patents, check exclusivity, and move on. But if you’re in business development, licensing, or competitive intellig…

Biotech investors love “pipeline value,” but most portfolio rankings still miss the point: value is not just what you own—it’s what you can recover from it, and how quickly.
That’s where two unglamorous finance tools—Net Present Value (NPV) and the Pro…

The “patent cliff” isn’t just a pharma problem—it’s a talent problem.
When blockbuster drugs lose exclusivity, the headlines focus on revenue, pricing pressure, and pipeline triage. But there’s another cliff that rarely gets discussed: the talent cliff…

Overstocking branded drugs isn’t just a balance-sheet problem—it’s a patent-timing problem.
For wholesalers, the risk isn’t theoretical. It shows up as expensive inventory that can’t be sold at the expected margin, write-downs that hit quarterly earnin…

Big Pharma doesn’t just “restructure” when a patent cliff hits. It repositions—and the earliest signal often isn’t in earnings calls. It’s in hiring.
Here’s the hidden hiring signal many investors and operators miss: patent cliff events don’t only chan…

Biosimilars are no longer a “someday” play. They’re a sourcing strategy.
If you’re still treating biosimilar switching as a procurement afterthought, you’re likely paying the price twice: first in missed timing, then in avoidable supply and contracting…

Pharma has a familiar playbook: take an old molecule, repackage it as “new,” and price it like it’s never been seen before.
In a world where patients, payers, and policymakers are increasingly focused on drug affordability, the industry’s justification…